Divis Labs Q3 Results Preview: Firm likely to see healthy growth due to low base
Divis Labs Q3 Preview: EBITDA, or earnings before interest, taxes, depreciation, and amortisation, is seen surging 38 per cent YoY to Rs 562 crore
Divi's Labs Q3 Preview: Divi's Laboratories, which is slated to release its December quarter (Q4 FY24) results on Saturday, February 10, is expected to put up a healthy set of numbers due to a low base and a ramp-up in new projects.
According to Zee Business Research, the pharmaceutical company will post a 33 per cent jump in consolidated profit after tax (PAT) or net profit to Rs 410 crore against Rs 307 crore registered in the year-ago period. Revenue for the period is expected to grow by 17 per cent YoY to Rs 1,994 crore as compared to Rs 1,708 crore recorded in the corresponding quarter of the previous fiscal.
EBITDA, or earnings before interest, taxes, depreciation, and amortisation, is seen surging 38 per cent YoY to Rs 562 crore, while margins for the quarter under review are seen at 28 per cent against 24 per cent in Q3 FY23.
Key monitorables include the pricing of generic API portfolios and the company's pipeline.
Divi's Lab share price
Shares of the pharma company have gained around 30 per cent over the past 12 months. In comparison, the benchmark Nifty50 has risen around 22 per cent. The Nifty Pharma index during the window has zoomed over 51 per cent.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.